AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Hart, L. A. [1 ]
Carlson, J. J. [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN135
引用
收藏
页码：A111 / A111
页数：1
相关论文
共 50 条
  • [21] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Santoni, Matteo
    Aurilio, Gaetano
    Massari, Francesco
    Grande, Enrique
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Incorvaia, Lorena
    Martignetti, Angelo
    Molina-Cerrillo, Javier
    Zabalza, Ignacio Ortego
    Mollica, Veronica
    Rizzo, Alessandro
    Battelli, Nicola
    Porta, Camillo
    CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
  • [22] Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
    Hao, Wang
    Ye, Wang
    Li, Li
    Han, Zhou
    Shang, Lili
    Li, Liao
    Shen, Yike
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [23] The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma
    Zaccagnino, Angela
    Vynnytska-Myronovska, Bozhena
    Stoeckle, Michael
    Junker, Kerstin
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 102 - 102
  • [24] The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
    Swallow, Elyse
    Messali, Andrew
    Ghate, Sameer
    McDonald, Evangeline
    Duchesneau, Emilie
    Perez, Jose Ricardo
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (04): : 335 - +
  • [25] Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma
    Chedgy, Edmund C. P.
    Black, Peter C.
    UROLOGY, 2016, 89 : 8 - 9
  • [26] Cabozantinib Approved for First-Line Treatment of Advanced Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 96 - 96
  • [27] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
  • [28] Multi-Target Kinase Inhibitor Cabozantinib New effective Option for Second-line Therapy of advanced Renal Cell Carcinoma
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 58 - 60
  • [29] Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma
    Tremblay, Gabriel
    McElroy, Heather J.
    Westley, Tracy
    Meier, Genevieve
    Misurski, Derek
    Guo, Matthew
    PLOS ONE, 2019, 14 (03):
  • [30] Second-line treatment of advanced neuroendocrine carcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (04): : 304 - 304
12345